BRAF and metastatic colorectal cancer: In the multicentre randomised Phase II/III FOCUS4-D trial, 32 patients with metastatic colorectal cancers WT for BRAF, PIK3Ca, KRAS and NRAS after first line induction therapy were randomised 1:1 to either AZD8931 40 mg bd continuous dosing regimen vs placebo.